Display options
Share it on

Health Sci Rep. 2021 Sep 18;4(3):e358. doi: 10.1002/hsr2.358. eCollection 2021 Sep.

Hepatitis C virus testing in a clinical HIV cohort in Ontario, Canada, 2000 to 2015.

Health science reports

Nasheed Moqueet, Ramandip Grewal, Tony Mazzulli, Curtis Cooper, Sandra L Gardner, Irving E Salit, Abigail Kroch, Ann N Burchell,

Affiliations

  1. MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital Unity Health Toronto Toronto Ontario Canada.
  2. Department of Microbiology Mount Sinai Hospital and University Health Network Toronto Ontario Canada.
  3. Public Health Ontario Toronto Ontario Canada.
  4. Toronto General Hospital University Health Network Toronto Ontario Canada.
  5. Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada.
  6. The Ottawa Hospital-Division of Infectious Diseases Ottawa Ontario Canada.
  7. Dalla Lana School of Public Health University of Toronto Toronto Ontario Canada.
  8. Rotman Research Institute Toronto Ontario Canada.
  9. The Ontario HIV Treatment Network Toronto Ontario Canada.
  10. Department of Family and Community Medicine, Faculty of Medicine University of Toronto Toronto Ontario Canada.

PMID: 34568583 PMCID: PMC8449285 DOI: 10.1002/hsr2.358

Abstract

BACKGROUND: HIV-positive individuals may acquire HCV via injection drug use (IDU) and condomless anal sex. HIV care provides opportunities for HCV testing and cure with direct-acting antiviral agents (DAAs).

METHODS: We analyzed data from the Ontario HIV Treatment Network Cohort Study. Among those not HCV-positive or diagnosed previously (n = 4586), we used Cox regression to test the rates of ever HCV testing (serological or RNA) in HIV care by DAA era (pre-DAA: 2000-2010; after DAA: 2011-2015) and compared the proportion diagnosed with HCV. We identified correlates of annual proportions of serological testing using Poisson generalized estimating equations.

RESULTS: After DAA vs pre-DAA, the hazard rate ratio (95% CI) of ever HCV testing was 1.70 (1.59, 1.81). The proportion (95% CI) tested annually increased from 9.2% (8.0%, 10.7%) in 2000 to 39.1% (37.1%, 41.1%) in 2015 (

DISCUSSION: Annual HCV testing increased over time with higher testing among those reporting sexual or IDU risk factors, but fell short of clinical guidelines. Targeted interventions to boost testing may be needed to close these gaps and reach WHO 2030 HCV elimination targets.

© 2021 The Authors. Health Science Reports published by Wiley Periodicals LLC.

Keywords: Coinfection/epidemiology; HIV infections/epidemiology*; HIV‐HCV co‐infection; hepatitis C virus testing; hepatitis C/epidemiology*

Conflict of interest statement

None to declare.

References

  1. Can Commun Dis Rep. 2014 Dec 18;40(19):429-436 - PubMed
  2. MMWR Recomm Rep. 1999 Aug 20;48(RR-10):1-59, 61-6 - PubMed
  3. Int J Epidemiol. 2013 Apr;42(2):402-11 - PubMed
  4. Am J Public Health. 2015 Aug;105(8):1604-10 - PubMed
  5. Clin Infect Dis. 2014 Jan;58(1):e1-34 - PubMed
  6. Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S63-8 - PubMed
  7. J Viral Hepat. 2018 Dec;25(12):1472-1480 - PubMed
  8. Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):17-22 - PubMed
  9. Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):311-20 - PubMed
  10. BMC Public Health. 2010 Apr 29;10:225 - PubMed
  11. Open Med. 2009;3(4):e184-95 - PubMed
  12. BMC Med Res Methodol. 2013 Mar 05;13:31 - PubMed

Publication Types